SCHEMBL13010265

SCHEMBL13010265

CCc1ccc2cccc(Cl)c2n1

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 2/20 0.54
FAAH O00519 1/20 0.42
XPO1 O14980 2/20 0.42
HDAC1 Q13547 1/20 0.41
HDAC2 Q92769 1/20 0.41
HDAC8 Q9BY41 1/20 0.41
HDAC6 Q9UBN7 1/20 0.41
AR P10275 1/20 0.40
CCR1 P32246 2/20 0.38
PDE10A Q9Y233 3/20 0.36
NR4A2 P43354 2/20 0.35
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
CYP1A2 P05177 1/20 0.34
CYP2A6 P11509 1/20 0.34
LMNA P02545 1/20 0.34
BDKRB2 P30411 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14126759 0.85 PDE10A (0.41) PARP1FAAHXPO1HDAC1HDAC2
SCHEMBL9018925 0.82 FAAH (0.43) PARP1FAAHXPO1HDAC1HDAC2
SCHEMBL14125329 0.81 HDAC1 (0.51) PARP1FAAHXPO1HDAC1HDAC2
SCHEMBL5365121 0.81 FAAH (0.42) PARP1FAAHXPO1HDAC1HDAC2
SCHEMBL29518341 0.81 CCR1 (0.63) PARP1FAAHXPO1HDAC1HDAC2
SCHEMBL28887382 0.81 FAAH (0.42) PARP1FAAHXPO1HDAC1HDAC2
SCHEMBL201143 0.81 CCR1 (0.63) PARP1FAAHXPO1HDAC1HDAC2
SCHEMBL17179178 0.81 FAAH (0.42) PARP1FAAHXPO1HDAC1HDAC2
SCHEMBL1702529 0.81 XPO1 (0.47) PARP1FAAHXPO1HDAC1HDAC2
SCHEMBL14094659 0.80 FAAH (0.40) PARP1FAAHXPO1HDAC1HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230158005-A1 Substituted Azole Dione Compounds with Antiviral Activity STEMLINE THERAPEUTICS, INC. (US) 2023-05-25 US disclosed
US-20170066783-A1 Aryl, Heteroaryl, and Heterocyclic Compounds for Treatment of Medical Disorders ACHILLION PHARMACEUTICALS, INC. (US) 2017-03-09 US disclosed
WO-2015154169-A1 BINDING FUNCTION3 (BF3) SITE COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2015-10-15 WO disclosed
EP-2261214-A1 Compounds useful to treat premature aging and in particular progeria Splicos Sas (FR) 2010-12-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170066783-A1 Aryl, Heteroaryl, and Heterocyclic Compounds for Treatment of Medical Disorders CFD, F12, F3 PARP1 2445/4885FAAH 1140/4885XPO1 1441/4885
US-20230158005-A1 Substituted Azole Dione Compounds with Antiviral Activity MAVS, DDX18, ZC3HAV1 PARP1 1591/4885FAAH 4254/4885XPO1 302/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.